Peptide Therapeutics: Contract API manufacturing market is projected to grow at an annualized rate of ~11.2%>>>

Roots Analysis has done a detailed study on Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030, covering various important aspects of the industry and identifying key future growth opportunities
To order this 250+ page report, which features 100+ figures and 110+ tables, please visit this link
Key Market Insights 
  • In the past few years, over 1,200 trials, enrolling close to 0.2 million patients suffering from a myriad of disease indications, have been registered globally to evaluate peptide-based drugs
  • Currently, around 50 companies claim to manufacture peptide-based therapeutics; such players also claim to be capable of providing a variety of additional services to their clients
  • The market landscape features the presence of multiple well-established players, most of which claim to operate across all scales of operation, having expertise in more than one method of peptide synthesis and purification
  • In order to cater to the growing needs of clients / sponsors, companies have established their presence across different regions; presently, the US, the Netherlands and Switzerland are the hubs for peptide production
  • Contract manufacturers are actively investing in expanding / upgrading existing capabilities and capacity; manufacturing peptide drugs was observed to be the focus of majority of recently inked deals in this domain
  • The current, installed global manufacturing capacity for peptide therapeutics is estimated to be more than 0.15 million liters
  • Peptide API drug developers are anticipated to continue to outsource their manufacturing operations in the mid to long term, resulting in an annualized growth rate of over 11.2% within the contract service market
For more information, please visit https://www.rootsanalysis.com/reports/view_document/peptide-therapeutics-manufacturing/305.html
 
Table of Contents
 
1.                     PREFACE
1.1.                   Scope of the Report
1.2.                   Research Methodology
1.3.                   Chapter Outlines
 
2.                     EXECUTIVE SUMMARY
 
3.                     INTRODUCTION
3.1.                   Chapter Overview
3.2.                   Overview of Peptides
3.2.1.                Structural Analysis of Peptides
3.2.2.                Type of Classes
3.2.3.                Peptide Synthesis
 
3.2.4.                Peptide Modification
3.2.4.1.             N-terminal Modification
3.2.4.2.             Internal Modification
3.2.4.3.             C-terminal Modification
3.2.4.4.             Other Modification
3.2.5.                Peptide Purification
3.2.5.1.             Peptide Purity Guidelines
3.3.                   Overview of Contract Manufacturing
3.3.1.                Need for Outsourcing in the Peptide Industry
3.3.2.                Key Considerations for Selecting a CMO Partner
3.3.3.                Advantages of Outsourcing Manufacturing Services
3.3.4.                Risks and Challenges Associated with Outsourcing Peptide Manufacturing                                   Services
3.4.                   Future Perspectives
 
4.                     REGULATORY LANDSCAPE
4.1.                   Chapter Overview
4.2.                   Regulatory Scenario: North America
4.2.1.                The US Scenario
4.2.1.1.             Overview
4.2.1.2.             General Guidelines
4.3.                   Regulatory Scenario: Europe
4.3.1.                The European Scenario
4.3.1.1.             Overview
4.3.1.2.             General Guidelines
4.4.                   Regulatory Scenario: Asia Pacific
4.4.1.                Overview
4.4.2.                Australian Scenario
4.4.2.1.             General Guidelines
4.4.3.                Chinese Scenario
4.4.3.1.             General Guidelines
4.4.4.                Indian Scenario
4.4.4.1.             General Guidelines
4.4.5.                Japanese Scenario
4.4.5.1.             General Guidelines
4.4.6.                South Korean Scenario
4.4.6.1.             General Guidelines
 
4.5.                   Challenges Associated with Peptide Manufacturing
 
5.                     COMPETITIVE LANDSCAPE
5.1                    Chapter Overview
5.2                    Contract Peptide API Manufacturers: Overall Market Landscape
5.2.1.                Analysis by Year of Establishment
5.2.2.                Analysis by Company Size
5.2.3.                Analysis by Location of Headquarters
5.2.4.                Analysis by Location of Manufacturing Facilities
5.2.5.                Analysis by Scale of Operation
           
5.2.6.                Analysis by Peptide Synthesis Method Used
5.2.7.                Analysis by Peptide Modification Services Offered
5.2.8.                Analysis by Purification Technology Used
5.2.9.                Analysis by Regulatory Accreditations / Certifications
5.3.                   List of Custom Peptide Manufacturers
6.                     COMPANY PROFILES
6.1                    Chapter Overview
6.2.                   Contract Peptide API Manufacturers Based in North America
6.2.1.                AmbioPharm
6.2.1.1.             Company Overview
6.2.1.2.             Service Portfolio
6.2.1.3.             Manufacturing Facilities and Capabilities
6.2.1.4.             Recent Development and Future Outlook
6.2.2.                CPC Scientific
6.2.2.1.             Company Overview
6.2.2.2.             Service Portfolio
6.2.2.3.             Manufacturing Facilities and Capabilities
6.2.2.4.             Recent Developments and Future Outlook
6.2.3.                Creative Peptides
6.2.3.1.             Company Overview
6.2.3.2.             Service Portfolio
6.2.3.3.             Manufacturing Facilities and Capabilities
6.2.3.4.             Recent Developments and Future Outlook
6.2.4.                CSBio
6.2.4.1.             Company Overview
6.2.4.2.             Service Portfolio
6.2.4.3.             Manufacturing Facilities and Capabilities
6.2.4.4.             Recent Developments and Future Outlook
6.3.                   Contract Peptide API Manufacturers Based in Europe
6.3.1.                Bachem
6.3.1.1.             Recent Developments and Company Overview
6.3.1.2.             Service Portfolio
6.3.1.3.             Manufacturing Facilities and Capabilities
6.3.1.4.             Recent Developments and Future Outlook
6.3.2.                BCN Peptide
6.3.2.1.             Company Overview
6.3.2.2.             Service Portfolio
6.3.2.3.             Manufacturing Facilities and Capabilities
6.3.2.4.             Recent Developments and Future Outlook
6.3.3.                Corden Pharma
6.3.3.1.             Company Overview
6.3.3.2.             Service Portfolio
6.3.3.3.             Manufacturing Facilities and Capabilities
6.3.3.4.             Recent Developments and Future Outlook
6.3.4.                PolyPeptide
6.3.4.1.             Company Overview
6.3.4.2.             Service Portfolio
6.3.4.3.             Manufacturing Facilities and Capabilities
6.3.4.4.             Recent Developments and Future Outlook
6.3.5.                Senn Chemicals
6.3.5.1.             Company Overview
6.3.5.2.             Service Portfolio
6.3.5.3.             Manufacturing Facilities and Capabilities
6.3.5.4.             Recent Developments and Future Outlook
6.4.                   Contract Peptide API Manufacturers Based in Asia Pacific
6.4.1.                Auspep
6.4.1.1.             Company Overview
6.4.1.2.             Service Portfolio
6.4.1.3.             Manufacturing Facilities and Capabilities
6.4.1.4.             Recent Developments and Future Outlook
6.4.2.                Chinese Peptide
6.4.2.1.             Company Overview
6.4.2.2.             Service Portfolio
6.4.2.3.             Manufacturing Facilities and Capabilities
6.4.2.4.             Recent Developments and Future Outlook
6.4.3.                Hybio Pharmaceutical
6.4.3.1.             Company Overview
6.4.3.2.             Service Portfolio
6.4.3.3.             Manufacturing Facilities and Capabilities
6.4.3.4.             Recent Developments and Future Outlook
6.4.4.                Peptide Institute
6.4.4.1.             Company Overview
6.4.4.2.             Service Portfolio
6.4.4.3.             Manufacturing Facilities and Capabilities
6.4.4.4.             Recent Developments and Future Outlook
6.4.5.                ScinoPharm
6.4.5.1.             Company Overview
6.4.5.2.             Service Portfolio
6.4.5.3.             Manufacturing Facilities and Capabilities
6.4.5.4.             Recent Developments and Future Outlook
 
7.                     RECENT DEVELOPMENTS
7.1.                   Chapter Overview
7.2.                   Partnerships Models
7.3.                   List of Partnerships and Collaborations
7.3.1.                Analysis by Year of Partnership
7.3.2.                Analysis by Type of Partnership
7.3.3.                Analysis by Scale of Manufacturing (Deal Specific)
7.3.4.                Analysis by Regional Distribution
7.3.4.1.             Country-Wise Distribution
7.3.4.2.             Intercontinental and Intracontinental Deals
7.4.                   Expansion Models
7.5.                   List of Recent Expansions
7.6.                   Emerging Peptide Synthesis Technologies
7.6.1.                Chemo-Enzymatic Peptide Synthesis Technology
7.6.2.                Continuous Flow Technology
7.6.3.                Green Chemistry
 
8.                     CLINICAL TRIAL ANALYSIS
8.1.                   Chapter Overview
8.2.                   Scope and Methodology
8.3                    Peptide Therapeutics: Clinical Trial Analysis
8.3.1.                Analysis by Trial Registration Year
8.3.2.                Analysis by Trial Recruitment Status
8.3.3.                Analysis by Trial Phase
8.3.4.                Analysis by Therapeutic Area
8.3.5.                Analysis by Geography
8.3.6.                Geographical Analysis by Trial Recruitment Status
8.3.8.                Geographical Analysis of Active Trials by Trial Phase
8.4.                   Peptide Therapeutics: Analysis of Enrolled Patient Population
8.4.1.                Analysis by Trial Registration Year
8.4.2.                Analysis by Trial Phase
8.4.3.                Analysis by Trial Registration Year and Trial Status
8.4.4.                Analysis by Therapeutic Area
8.4.5.                Analysis by Location of Trial Site
8.4.6.                Analysis by Trial Status and Location of Trial Site
8.4.7.                Analysis of Active Trials by Trial Phase and Location
8.5.                   Analysis by Type of Sponsor / Collaborator
8.6.                   Analysis by Clinical Trial Center
 
9.                     REGIONAL CAPABILITY ANALYSIS    
9.1.                   Chapter Overview
9.2.                   Key Assumptions and Methodology
9.3.                   Overall Landscape of Contract Peptide API Manufacturers
9.4.                   Regional Capability Analysis: Contract Peptide API Manufacturers in North                                  America
9.5.                   Regional Capability Analysis: Contract Peptide API Manufacturers in Europe
9.6.                   Regional Capability Analysis: Contract Peptide API Manufacturing in Asia                                    Pacific
 
10.                    DEMAND ANALYSIS
10.1.                 Chapter Overview
10.2.                 Assumptions and Methodology
10.3.                 Peptide API Manufacturing: Overall Annual Demand
10.3.1.              Analysis by Geography
 
11.                    CAPACITY ANALYSIS                                      
11.1.                 Chapter Overview
11.2.                 Assumptions and Methodology
11.3.                 Peptide API Manufacturing: Installed Global Capacity
11.3.1.              Analysis by Company Size
11.3.2.              Analysis by Scale of Operation
11.3.3.              Analysis by Location of Manufacturing Facility
11.3.4.              Analysis by Company Size and Location of Manufacturing
11.3.5.              Analysis by Scape of Operation and Location of Manufacturing Facility
11.4.                 Concluding Remarks
 
12.                    MAKE VERSUS BUY DECISION MAKING FRAMEWORK
12.1.                 Chapter Overview
12.2.                 Assumptions and Parameter Definitions
12.2.1.              Scenario 1
12.2.2.              Scenario 2
12.2.3.              Scenario 3
12.2.4.              Scenario 4
12.3.                 Concluding Remarks
 
13.                    MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1.                 Chapter Overview
13.2.                 Assumptions and Forecast Methodology
13.3.                 Overall Contract Peptide Manufacturing Market, 2020-2030
13.3.1.              Contract Peptide Manufacturing Market for Peptide API Manufacturing, 2020-                               2030
13.3.2.              Contract Peptide Manufacturing Market for Peptide FDF Manufacturing, 2020-                              2030
13.4.                 Contract Peptide API Manufacturing Market, 2020-2030: Distribution by Scale of Operation                     
13.5.                 Contract Peptide API Manufacturing Market, 2020-2030: Distribution by Peptide Synthesis Method Used
13.5.1.              Contract Peptide API Manufacturing Market, 2020-2030: Distribution by Chemical Synthesis Method Used               
13.6.                 Contract Peptide API Manufacturing Market, 2020-2030: Distribution by End User
13.7.                 Contract Peptide API Manufacturing Market, 2020-2030: Distribution by Key Geographical Regions           
13.7.1.              Contract Peptide API Manufacturing Market in North America, 2020-2030
13.7.1.1.           Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Small Companies
13.7.1.2.           Contract Peptide API Manufacturing Market in North America,2020-2030: Share of Mid-sized Companies           
13.7.1.3.           Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies
13.7.1.4.           Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.7.1.5.           Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations
13.7.1.6.           Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Chemical Synthesis Methods
13.7.1.7.           Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Non-Chemical Synthesis Methods
13.7.2.              Contract Peptide API Manufacturing Market in Europe, 2020-2030
13.7.2.1.           Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Small Companies
13.7.2.2.           Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies           
13.7.2.3.           Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies
13.7.2.4.           Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.7.2.5.           Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations
13.7.2.6.           Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Chemical Synthesis Methods
13.7.2.7.           Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Non-Chemical Synthesis Methods
13.7.3.              Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030
13.7.3.1.           Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Small Companies
13.7.3.2.           Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Mid-sized Companies           
13.7.3.3.           Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Large / Very Large Companies
13.7.3.4.           Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.7.3.5.           Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Scale Operations
13.7.3.6.           Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Chemical Synthesis Methods
13.7.3.7.           Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Non-Chemical Synthesis Methods
 
14.                    IMPACT OF THE COVID-19 PANDEMIC ON THE PEPTIDE API CONTRACT MANUFACTURING MARKET
14.1.                 Chapter Overview
14.2.                 Current Options and Recuperative Initiatives of Key Players
14.2.1.              Bachem
14.2.2.              CPC Scientific
14.2.3.              Corden Pharma
14.2.4.              PolyPeptide
14.2.5.              Wuxi AppTec
 
14.3.                 Impact on Peptide API Contract Manufacturing Market Opportunity
 
15.                    SWOT ANALYSIS
15.1.                 Chapter Overview
15.2.                 Strengths
15.3.                 Weaknesses
15.4.                 Opportunities
15.5.                 Threats
15.6.                 Comparison of SWOT Factors
15.7.                 Concluding Remark
 
16.                    CONCLUSION
16.1.                 Chapter Overview
16.2.                 Key Takeaways
 
17.                    SURVEY TRANSCRIPT(S)
 
18.                    APPENDIX 1: TABULATED DATA
 
19.                    APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS
 
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]


You may also like

Discussion

No comments yet... Be the first to leave a reply! Login here

avatar
BenJ
0 Karma
755 Posts

Made with by Mamby